Generic Zomig-ZMT Availability
See also: Generic Zomig
ZOMIG-ZMT (zolmitriptan - tablet, orally disintegrating; oral)
Approval date: February 13, 2001
Approval date: September 17, 2001
Strength(s): 5MG [RLD]
Has a generic version of Zomig-ZMT been approved?
No. There is currently no therapeutically equivalent version of Zomig-ZMT available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zomig-ZMT. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Indolyl compounds for treating migraine
Issued: November 14, 1995
Inventor(s): Robertson; Alan D. & Hill; Alan P. & Glen; Robert C. & Martin; Graeme R.
Assignee(s): Burroughs Wellcome Co.
##STR1## The present invention is concerned with compounds of formula (I), wherein n is an integer of from 0 to 3: W is a group of formula (i), (ii), or (iii), wherein R is hydrogen or C.sub.1-4 alkyl, X is --O--, --S--, --NH--, or --CH.sub.2 --, Y is oxygen or sulphur and the chiral center (*) in formula (i) or (ii) is in its (S) or (R) form or is a mixture thereof in any proportions: and Z is a group of formula (iv), (v), or (vi), wherein R.sup.1 and R.sup.2 are independently selected from hydrogen and C.sub.1-4 alkyl and R.sup.3 is hydrogen or C.sub.1-4 alkyl; and their salts, solvates and physiologically functional derivatives, with processes for their preparation, with medicaments containing them and with their use as therapeutic agents, particularly in the prophylaxis and treatment of migraine.Patent expiration dates:
- November 14, 2012
- May 14, 2013✓
- November 14, 2012
- Zomig ZMT orally disintegrating tablets Consumer Information (Wolters Kluwer)
- Zomig-ZMT Consumer Information (Cerner Multum)
- Zomig-ZMT Advanced Consumer Information (Micromedex)
- Zolmitriptan Consumer Information (Wolters Kluwer)
- Zolmitriptan orally disintegrating tablets Consumer Information (Wolters Kluwer)
- Zolmitriptan spray Consumer Information (Wolters Kluwer)
- Zolmitriptan Consumer Information (Cerner Multum)
- Zolmitriptan nasal Consumer Information (Cerner Multum)
- Zolmitriptan Advanced Consumer Information (Micromedex)
- Zolmitriptan AHFS DI Monographs (ASHP)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|